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Objective: This study evaluated the tolerability and efficacy of inhaled AZD4818, a CCR1
antagonist, in patients with COPD.
Methods: This double-blind, placebo-controlled study (NCT00629239) randomised patients with
moderate to severe COPD to AZD4818 300 mg or placebo twice daily via Turbuhaler for 4 weeks.
Safety, lung function, functional capacity and health status measures were measured. Plasma
concentrationsofAZD4818weremeasuredafter thefirst doseandafter2and4weeks’ treatment.
Results: Sixty-five patients (47 male; median age 65.6 years) received AZD4818 (nZ 33) or
placebo (nZ 32). Therewas no statistically significant difference between AZD4818 and placebo
in change frombaseline to endpoint for FEV1 (AZD4818eplacebo: 0.026 L, pZ 0.69),morning PEF
(6 L/min, pZ 0.23), or other lung function measures. There was no difference between treat-
ment groups in the 6-min walk test, MMRC dyspnoea index, BODE index and CCQ scores. Plasma
concentrations indicated that patients were exposed to AZD4818 as expected. AZD4818 was well
tolerated: 27 treatment-related adverse events (13 with AZD4818, 14 with placebo), 2 serious
adverse events (both AZD4818: exacerbation [considered not treatment-related] and deep vein
thrombosis [considered treatment-related]) and 11 discontinuations (7 with AZD4818).
Conclusions: Inhaled AZD4818 was well tolerated at 300 mg twice daily for 4 weeks in patients
with COPD; however, there was no indication of a beneficial treatment effect despite exposure
as expected. These findings in COPD are in line with other studies reporting a lack of clinical
efficacy with CCR1 antagonists in other therapy areas.
ª 2010 Elsevier Ltd. All rights reserved.36 10280; fax: þ31 50 36 19320.
ong.umcg.nl (H.A. Kerstjens).
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Chronic obstructive pulmonary disease (COPD) is a progres-
sive lung disorder characterised by increasing airflow limi-
tation that is not fully reversible. Current treatments
(bronchodilators and anti-inflammatory agents) to some
degree relieve symptoms, decrease airflow limitation, and
reduce exacerbation frequency but are unable to alter the
progression of the disease.
The disease is driven by an inflammatory process
accompanied by small airway changes, destruction of lung
parenchyma, loss of lung elasticity and enlargement of air
spaces. As such, the inflammatory component of COPD may
be a target for disease modification. A key element of the
inflammatory component of COPD involves the infiltration
of lung tissue by inflammatory cells including neutrophils,
monocytes and macrophages. These cells are dependent, in
part, on the function of the CCR1 chemokine receptor for
recruitment and activation in lung tissue.1e3
We report here the results of a 4-week study designed to
evaluate the tolerability and efficacy of inhaled AZD4818,
an inhaled CCR1 chemokine receptor antagonist, in patients
with moderate to severe COPD.
Methods
This was a phase IIa, 4-week, double-blind, placebo-
controlled, randomised, parallel-group study (NCT00629239)
of inhaledAZD4818 in patientswithmoderate to severeCOPD
conducted across 11 sites in Northern and Western Europe
(Fig. 1).
Patients
Patients who were current or ex-smokers with at least 10
pack years of smoking, aged 40 years with a confirmed65 randomized
51 not meeting inclusion criteria
6 adverse events
5 refused to participate
2 other
AZD4818
33 allocated to 
treatment
Placebo
32 allocated to 
treatment
7 discontinuations
7 adverse events
129 patients assessed for 
eligibility
4 discontinuations
4 adverse events
26 completed 28 completed
Figure 1 Patient flow diagram.diagnosis of COPD and a symptom duration >12 months
were eligible for inclusion in the current study. In addition,
patients were required to have a post-bronchodilator
forced expiratory volume in 1 second (FEV1) of 40e80% of
the predicted normal value and a post-bronchodilator
FEV1/forced vital capacity (FVC) <70%, daily breathlessness
score 1 on at least half of the run-in period and a history
of short acting b2-agonist or anticholinergic use as rescue
medication.
Individuals with a COPD exacerbation within the 30 days
prior to study commencement (including use of an oral or
systemic glucocorticosteroid), a requirement for regular
oxygen therapy, current respiratory tract disorders other
than COPD, clinical suspicion of tuberculosis, history of
cardiac disorders, malignancy within the past 5 years, or
alcohol or drug abuse were not eligible to take part.
Additional exclusion criteria included a disease history
suggesting impaired immune function and known or sus-
pected hypersensitivity to the study therapy or excipients
(e.g. benzoate, lactose).
Upon enrolment, patients’ ordinary COPD medication
was withdrawn and patients undertook a 2-week wash-out
period prior to randomisation. Terbutaline as rescue
medication, ipratropium bromide as maintenance treat-
ment, and nasal and dermal glucocorticosteroids were
allowed. Prohibited medication included oral, inhaled or
systemic glucocorticosteroids, b2-agonists other than ter-
butaline, anticholinergics other than ipratropium bromide,
leukotriene antagonists, non-selective b-blockers, medica-
tion that prolongs the QT/QTc interval other than inhaled
b2-agonists, medication containing ephedrine, mucolytics
and theophyline.
Study treatments
Patients received either AZD4818 300 mg (two inhalations of
150 mg/dose) as a dry powder for inhalation via Turbuhaler
twice daily, or matching placebo. Patients were also
permitted terbutaline (Bricanyl Turbuhaler) (0.5 mg/
dose) as needed and ipratropium bromide as maintenance
treatment throughout the study although neither were to
be used within 6 and 8 h, respectively, prior to a study visit.
Study endpoints
The primary objective of the study was to investigate the
tolerability and safety of inhaled AZD4818 in COPD patients
by assessment of the incidence and severity of adverse
events, electrocardiograph (ECG), vital signs and laboratory
assessments (clinical chemistry, haematology and urinal-
ysis). Adverse events were scored by the investigators while
still blinded as related with reasonable possibility or not to
the investigational drug.
The secondary objective of the study was to evaluate
the effects of inhaled AZD4818 on lung function among
COPD patients. Functional assessments included FEV1, FVC,
mean forced expiratory flow between 25% and 75% of the
FVC (FEF25e75%), vital capacity (VC), inspiratory capacity
(IC) and peak expiratory flow (PEF).
Functional capacity was determined using the 6-min
walk test (6MWT); BODE index score (a composite score of
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dyspnoea [as assessed by the Modified Medical Research
Council (MMRC) dyspnoea scale] and exercise capacity
(6MWT), total range 0e10) and Borg scale during exercise
(an assessment of dyspnoea and fatigue, range 0e10) were
also evaluated. Health status was assessed with the Clinical
COPD Questionnaire4 (CCQ, range 0e6), COPD symptoms
(breathlessness, cough, chest tightness and night-time
awakenings, range 0e7), diary rescue medication use.
Additional laboratory evaluations included blood cells and
soluble plasma inflammatory markers and plasma concen-
trations of AZD4818.
Assessmentof serumbiomarker levelswasperformedevery
2 weeks from randomisation using a multiplex analysis kit.
Statistical analysis
Descriptive statistics were used to express safety data with
adverse event data presented in terms of frequencies.
Other data were analysed using an analysis of variance
model with treatment and country as factors and baseline,
when relevant, as covariate. Assessment of effects on all
laboratory variables was based on the change from baseline
(last measurement during the run-in period) to end-of-
treatment (the last measurement during the treatment
period). For efficacy data, p-values and confidence limits
were also generated but were considered to be exploratory.
Results
In total, 65 patients were eligible for inclusion and were
randomised to study treatment (AZD4818 nZ 33, placebo
nZ 32). Patient flow and baseline characteristics are
summarized in Fig. 1 and Table 1.
Safety
Themajority of patients in both treatment arms experienced
at least one adverse event during the study (AZD4818 nZ 22
[67%], placebo nZ 27 [84%]); most weremild to moderate in
intensity (Table 2). There were no deaths recorded.
A total of 27 adverse events were regarded by the study
investigators as possibly related to study treatment.
Two serious adverse events were recorded, both in the
AZD4818 treatment arm. These included one case of COPD
exacerbation for which the patient required hospitalisation
but was not considered related to study treatment by the
investigator, and one case of deep vein thrombosis that was
considered possibly related to study treatment by the
investigator.
Eleven patients withdrew from the study due to an
adverse event, 7 (21%) in the AZD4818 group and 4 (13%) in
the placebo group.
Therewereno clinically relevant changes in vital signs, ECG
orsafety laboratoryvariables foreithergroupduringthe study.
Efficacy
There were no statistically significant differences between
treatment groups with respect to any of the lung function
assessments, functional capacity,modifiedMedical ResearchCouncil Dyspnoea Index, BODE index, Clinical COPD Ques-
tionnaire scores, diary card symptoms or rescue medication
use (Table 3, Fig. 2). While change inmorning PEF (diary card
data) did not differ significantly between the treatment
groups, change in evening PEF favoured placebo at the
endpoint.
Biomarker measurements
No clinically relevant differences between the two treat-
ment groups were noted in the mean change from baseline
in blood cells, including white cell counts and differentials,
or soluble mediators (see Supplementary Fig. S1).
Pharmacokinetics
All patients receiving inhaled AZD4818 had detectable
levels of the drug in their blood samples. The plasma
concentration profiles for individual patients indicated that
patients were exposed to AZD4818 as expected (see
Supplementary Fig. S2).
Discussion
AZD4818 at a dose of 300 mg twice daily via Turbuhaler was
well tolerated over a 4-week treatment period in COPD
patients. However, there was no indication of a beneficial
treatment effect of inhaled AZD4818 in terms of clinical
efficacy or changes in the number of inflammatory cells in
the blood or in other blood-based biomarkers of inflam-
mation. Plasma concentrations indicated that patients
were exposed as predicted and well above (70 times) the
estimated therapeutic dose in man of a lung deposited dose
of 5 mg, which was based on preclinical data from an LPS
challenge model in rats.5,6
During the development of AZD4818, in vitro and in vivo
data were encouraging. In vitro, AZD4818 inhibited the
binding of the CCR1 ligand MIP-1a to human, rat, mouse and
dog CCR1 receptors in a concentration-dependent manner.6
Moreover, AZD4818 inhibited chemotaxia of human mono-
cytes to MIP-1a in a concentration-dependent manner.6 In
vivo studies in rats were also encouraging with a significant
reduction of neutrophil influx and TNF-a levels on bron-
choalveolar lavage (BAL) following intratracheal adminis-
tration of AZD4818 (1 mg/kg) prior to LPS challenge.6 In an
animal LPS model, a dose-dependent reduction of leuko-
cyte infiltration in BAL fluid was observed following acute
delivery of inhaled nebulised AZD4818 (0.3e26 mg/kg) prior
to LPS challenge.5 In an acute 5-day smoke-exposure model
in mice, inhaled nebulised AZ11880492 (a structurally
similar chloro-analogue of AZD4818) caused a dose-depen-
dent inhibition of neutrophil influx into BAL of the cigarette
smoking mice (5 days model) at lung deposited doses
0.3 mg/kg (0.604 nmol/kg) body weight (49% inhibition of
neutrophil influx), 4.8 mg/kg (9.66 nmol/kg) (71% inhibition)
and 52 mg/kg (105 nmol/kg) (76% inhibition).6 In a chronic
LPS animal model, inhaled nebulised AZD4818 (0.01 mg/mL
[19.2 mM] and 1 mg/ml [1920 mM]) once daily for 5 days per
week for a period of 4 or 8 weeks significantly reduced
infiltrating BAL macrophage cell numbers in the 4-week as
well as the 8-week experiments.6
Table 1 Patients’ baseline demographics and disease characteristics.
Parameter AZD4818 (nZ 33) Placebo (nZ 32)
Gender
Male 23 24
Female 10 8
Mean age, years (range) 65.2 (51e78) 66.0 (42e77)
Mean BMI, kg/m2 (range) 25.2 (20e30) 25.0 (20e29)
Median time since diagnosis, years (range) 5.2 (0ae16) 6.2 (0ae15)
Smoking status
Previous 20 19
Habitual 13 13
Median pack years (range) 38 (16e60) 39.5 (11e92)
Inhaled GCS at entry
N 11 11
Dose, mg (range) 745.5 (320e1000) 661.8 (160e1000)
Lung function (range)
FEV1, % VC, post-br 1.52 (0.91e3.03) 1.64 (0.65e2.65)
FEV1, L, post-br 53.5 (34e77) 55.7 (38e76)
FEV1, % Pred, post-br 12.2 (7 to 37) 10.3 (3 to 35)
Reversibility, % Pred 45.8 (24e70) 47.3 (26e69)
Mean number of daily rescue inhalations 1.76 2.06
Mean breathlessness score (range) 1.57 (0.6e2.8) 1.64 (0.3e2.8)
BMI e body mass index; GCS e glucocorticosteroid; FEV1 e forced expiratory volume in 1 s post-br e post-bronchodilator; Pred e
predicted normal value; VC e vital capacity.
a Note that one of the inclusion criteria was COPD symptoms for at least 1 year; the symptoms had been present for at least 1 year for
all patients but not necessarily the diagnosis of COPD.
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results in humans for CCR1 antagonists may be the variable
cross-species reactivity of these agents.7e9 Indeed, there is
some evidence that CCR1 expression/functionality differs
between human and rodent neutrophils. For example,
a study with the CCR1 ligand MIP-1a revealed fundamental
differences in an animal model of respiratory disease in
terms of the mechanism of leukocyte priming.10 Such
findings would indicate that current in vivo animal models
may not be sufficiently reflective of equivalent human
CCR1-mediated processes to evaluate the action and effi-
cacy of CCR1 antagonists in humans. Human transgenic
mouse models may prove useful in this setting to identify
more potent CCR1-targeted agents and to define their
potential clinical profile.11 Other possible biological
explanations for the poor translation of efficacy resultsTable 2 Incidence of adverse events reported (5%).
Adverse event, n (%) patients
Increase in Chronic obstructive pulmonary disease symptomsa
Cough
Nasopharyngitis
Tremor
Dry mouth
Headache
Number of treatment-related adverse events
a Increase in COPD symptoms could be considered an AE if the sym
COPD history.from animal models to humans may include the dosing
route (oral versus inhaled) and redundancy of CCR1, as
CCR1 may not in fact be a critical chemokine in humans.8
For CCR1, it is possible that local delivery of an antago-
nist compound directly to the lung tissue in humans might
fail to inhibit the chemotactic gradient that facilitates the
infiltration of inflammatory cells. Thus, while an oral che-
mokine receptor antagonist, such as AZD8309,12 will act to
reduce inflammatory cell infiltration in humans, an inhaled
chemokine receptor antagonist may not.
The choice of efficacy variables (lung function and
symptom control) for the current study may also have
contributed to the failure to demonstrate any benefit for
active treatment. The clinical parameters chosen are fine
for detection and evaluation of bronchodilators but might
be limited in their detection of novel compounds. SputumAZD4818 (nZ 33) Placebo (nZ 32)
9 (27%) 3 (9%)
3 (9%) 7 (22%)
1 (3%) 8 (25%)
5 (15%) 0
2 (6%) 3 (9%)
3 (9%) 1 (3%)
13 14
ptoms were new or not consistent with the patient’s pre-existing
Table 3 Treatment comparison for efficacy variables.
Parameter Change from baseline Between treatment difference
AZD4818 Placebo Estimate (90% CI) P value
Adjusted differencea Adjusted differencea
Lung function, post-bronchodilator
FEV1, L 0.103 0.129 0.026 (0.084 to 0.137) 0.69
FVC, L 0.081 0.217 0.137 (0.037 to 0.310) 0.19
VC, L 0.037 0.119 0.083 (0.131 to 0.296) 0.52
IC, L 0.100 0.040 0.061 (0.220e0.099) 0.53
FEF25e75%, L/s 0.027 0.007 0.034 (0.112 to 0.043) 0.46
Functional capacity and health status
Walking distance, m 11.4 3.9 7.5 (29.8 to 14.8) 0.58
MMRC (dyspnoea) 0.08 0.01 0.08 (0.25 to 0.41) 0.68
BODE, total score 0.31 0.19 0.12 (0.38 to 0.62) 0.70
CCQ, total score 0.21 0.04 0.18 (0.18 to 0.53) 0.42
Diary variables: change between run-in and treatment period
Morning PEF, L/min 10.0 3.7 6.3 (15.0 to 2.4) 0.23
Evening PEF, L/min 13.7 0.8 12.9 (20.4 to 5.4) 0.01
COPD symptoms
Sleep score 0.07 0.02 0.09 (0.07 to 0.25) 0.35
Breathlessness 0.14 0.01 0.14 (0.06 to 0.34) 0.25
Cough score 0.04 0.10 0.14 (0.07 to 0.35) 0.27
Chest tightness 0.20 0.01 0.19 (0.02 to 0.40) 0.13
Use of rescue medication 0.03 0.06 0.030 (0.515 to 0.456) 0.92
CCQ e Clinical COPD Questionnaire; COPD e chronic obstructive pulmonary disease; FEV1 e forced expiratory volume in 1 s; FVC e
forced vital capacity; IC e inspiratory capacity; MMRC e Modified Medical Research Council; PEF e peak expiratory flow; VC e vital
capacity.
a Analysis of variance.
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order to come closer to the target organ, but for a multi-
centre study feasibility aspects also need to be considered
and for this reason it was not included. The duration of the
current study (4 weeks) was possibly too short to detect any
disease-modifying effects of AZD4818, such as an effect on
lower airway inflammation. Indeed, the study was not
adequately powered to detect any such disease-modifying
properties. The study was primarily designed to evaluate
safety of the drug, however, based on the efficacy in
preclinical studies it was anticipated that a positive effi-
cacy signal would be detected in trends rather than true
significant changes over time. The absence of any clinically
relevant changes in haematological markers of inflamma-
tion (blood cell counts or inflammatory biomarkers)
compared with placebo in the current study is in contrast
(for blood cell counts) with a previous (unpublished) study
with AZD4818 (see Supplementary information). The
possibility of chronic effects on sputum levels or the profile
of inflammatory cells in the current study cannot be ruled
out as they were not specifically evaluated. Moreover,
despite a prior observation of changes in the sputum
inflammatory cell profile following acute AZD4818 exposure
in a rat LPS challenge model,5 repeated dosing of AZD4818
in a double-blind, randomised, placebo-controlled, cross-
over study in healthy males (aged 18e45 years) found that
inhaled AZD4818 at 800 mg twice daily via Turbuhaler for 7
days did not reduce the numbers of neutrophils, monocytesand other white blood cells or the levels of inflammatory
markers in induced sputum and blood after LPS challenge.6
The current study evaluated the effect by AZD4818 as
monotherapy compared with placebo. However, CCR1 is
one of several chemokine receptors involved in neutrophilic
inflammation and blocking only one receptor may be
insufficient for to have sufficient biological effect. Hence,
it cannot be ruled out that additive or synergistic effects
might be achieved by combining the drug with other
mediator antagonists. Future research should explore the
potential for combined targeting of multiple chemokine
receptors for the treatment of diseases with an inflamma-
tory component.
In conclusion, inhaled AZD4818 was well tolerated at
300 mg twice daily for 4 weeks in patients with COPD;
however, there was no indication of a beneficial treatment
effect despite exposure as expected. These findings in
COPD are consistent with other studies that have reported
a lack of clinical efficacy with CCR1 antagonists, such as
BX471 for multiple sclerosis13,14 and CP-481715 for rheu-
matoid arthritis,15 in humans despite promising results in
animal models.16e18Conflict of interest
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